MEBHYDROLIN NAPADISILATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C19H20N2.C10H8O6S2
Molecular Weight	841.048
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(=O)(=O)C1=CC=CC2=C1C=CC=C2S(O)(=O)=O.CN3CCC4=C(C3)C5=C(C=CC=C5)N4CC6=CC=CC=C6.CN7CCC8=C(C7)C9=C(C=CC=C9)N8CC%10=CC=CC=C%10

InChI

InChIKey=CJUOSBUQOWKEKJ-UHFFFAOYSA-N

InChI=1S/2C19H20N2.C10H8O6S2/c2*1-20-12-11-19-17(14-20)16-9-5-6-10-18(16)21(19)13-15-7-3-2-4-8-15;11-17(12,13)9-5-1-3-7-8(9)4-2-6-10(7)18(14,15)16/h2*2-10H,11-14H2,1H3;1-6H,(H,11,12,13)(H,14,15,16)

HIDE SMILES / InChI

Molecular Formula	C19H20N2
Molecular Weight	276.3755
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H8O6S2
Molecular Weight	288.297
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.beximcopharma.com/images/stories/product-pdf/bexidal.pdf

Mebhydrolin (INN) or mebhydroline is a histamine H1-receptor antagonist. It is not available in the United States, but it is available in various other countries under the brand names Bexidal and Diazolin. It is used for symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 312 Target ID: CHEMBL231 Sources: http://www.rlsnet.ru/tn_index_id_1396.htm	Antagonist 2737

Conditions

Condition	Modality	Highest Phase	Product
Urticaria 38 Sources: http://www.beximcopharma.com/images/stories/product-pdf/bexidal.pdf	Primary	Approved 8307	Bexidal Approved Use Unknown
Allergic conjunctivitis 97 Sources: http://www.beximcopharma.com/images/stories/product-pdf/bexidal.pdf	Primary	Approved 8307	Bexidal Approved Use Unknown
Dermatitis of nutritional origin 2 Sources: http://www.beximcopharma.com/images/stories/product-pdf/bexidal.pdf	Primary	Approved 8307	Bexidal Approved Use Unknown
Vasomotor rhinitis 21 Sources: http://www.beximcopharma.com/images/stories/product-pdf/bexidal.pdf	Primary	Approved 8307	Bexidal Approved Use Unknown

PubMed

Title	Date	PubMed
Cutaneous reaction to oral antihistamine.	2003 Mar	12653725
Subcorneal pustular dermatosis: 50 years on.	2008 May	18355359

Sample Use Guides

In Vivo Use Guide

Adults and children over 10 years 2-6 tablets daily Children from 5-10 years 2-4 tablets daily Children from 2-5 years 1-3 tablets daily Children up to 2 years 1-2 tablets daily Treatment should be given in several single doses daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 17 01:51:43 UTC 2022` Edited by `admin` on `Sat Dec 17 01:51:43 UTC 2022`
Record UNII	O5G04RB25M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEBHYDROLIN NAPADISILATE

Common Name

English

MEBHYDROLIN NAPADISILATE [JAN]

Common Name

English

Mebhydrolin napadisilate [WHO-DD]

Common Name

English

MEBHYDROLINE 1,5-NAPHTHALENEDISULFONATE SALT

Common Name

English

5-BENZYL-1,3,4,5-TETRAHYDRO-2-METHYL-2H-PYRIDO(4,3-B)INDOLE, 1,5-NAPHTHALENEDISULFONATE SALT

Common Name

English

MEBHYDROLIN NAPADISYLATE

Common Name

English

OMERIL

Brand Name

English

DIAZOLINE

Systematic Name

English

MEBHYDROLINE 1,5-NAPHTHALENEDISULFONATE SALT [MI]

Common Name

English

FABAHISTIN

Brand Name

English

Code System Code Type Description

ECHA (EC/EINECS)

228-170-3